PC is one of the most deadly malignancies in the United States, with late clinical presentation, early metastasis, and poor prognosis. Although it takes more than 17 years for PC to progress from mutation to metastatic cancer, reliable early identification methods are lacking. If diagnosed early, providing a window of opportunity for early detection and thus potentially significantly improve overall survival. Here, we briefly describe the diagnostic strategies and the potential biomarkers for the early diagnosis of PC.
- Home
- Pancreatic Cancer
- Solutions
- By Target
- KRAS Inhibitor Development for Pancreatic Cancer
- RET Inhibitor Development for Pancreatic Cancer
- ROR1 Inhibitor Development for Pancreatic Cancer
- Claudin18.2 Inhibitor Development for Pancreatic Cancer
- BRAF Inhibitor Development for Pancreatic Cancer
- NTRK Inhibitor Development for Pancreatic Cancer
- CD39 Inhibitor Development for Pancreatic Cancer
- By Molecule Type
- Small Molecule Drug Development for Pancreatic Cancer
- Therapeutic Antibody Development for Pancreatic Cancer
- Therapeutic Monoclonal Antibody Development for Pancreatic Cancer
- Therapeutic Polyclonal Antibody Development for Pancreatic Cancer
- Therapeutic Bispecific Antibody Development for Pancreatic Cancer
- Therapeutic Single Domain Antibody Development for Pancreatic Cancer
- Therapeutic Antibody Fragment Development for Pancreatic Cancer
- Antibody Drug Conjugate (ADC) Development for Pancreatic Cancer
- Peptide Drug Development for Pancreatic Cancer
- Gene Therapy Development for Pancreatic Cancer
- Cell Therapy Development for Pancreatic Cancer
- Stem Cell Therapy Development Service for Pancreatic Cancer
- CAR-T Cell Therapy Development Service for Pancreatic Cancer
- TCR-T Therapy Development Service for Pancreatic Cancer
- CAR-NK Therapy Development Service for Pancreatic Cancer
- TIL Therapy Development Service for Pancreatic Cancer
- CAR-iMac Therapy Development Service for Pancreatic Cancer
- CIK Therapy Development Service for Pancreatic Cancer
- Therapeutics Vaccine Development for Pancreatic Cancer
- Whole-Cancer Cell Vaccine Development for Pancreatic Cancer
- iPSC-Based Vaccine Development for Pancreatic Cancer
- Dendritic Cell-Based Vaccine Development for Pancreatic Cancer
- Peptide-Based Vaccine Development for Pancreatic Cancer
- mRNA Vaccine Development for Pancreatic Cancer
- DNA Vaccine Development for Pancreatic Cancer
- Oncolytic Viral Therapy Development for Pancreatic Cancer
- By Research Phase
- Diagnostics Development for Pancreatic Cancer
- Biomarkers Identification for Pancreatic Cancer
- Omics Analysis for Pancreatic Cancer
- Microbiota as Diagnostic Biomarkers for Pancreatic Cancer
- Drug Discovery for Pancreatic Cancer
- Tumor Model Development for Pancreatic Cancer
- Cell Model for Pancreatic Cancer
- 3D Tumor Model for Pancreatic Cancer
- In Vivo Model Development for Pancreatic Cancer
- Preclinical Services for Pancreatic Cancer
- Pancreatic Cancer Basic Research Services
- Diagnostics Development for Pancreatic Cancer
- By Target
- About
- Contact Us